GlassScriptPhysician profile
Tiffini Lasch
NPI 1013650191
$3,277.90
in general payments reported to CMS, 2019-2025
19 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $935 · 2024: $1,667 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.90 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $561.09 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $414.76 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $397.07 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $332.49 | 2023-2025 | Auvelity |
| Lundbeck LLC | $235.26 | 2023-2025 | Rexulti |
| Alkermes, INC. | $216.31 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $207.95 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $172.68 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $159.97 | 2023-2024 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.29 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $117.35 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $97.34 | 2023-2025 | Trintellix |
| Tris Pharma INC | $76.44 | 2023 | Dyanavel Xr |
| Livanova USA, INC. | $75.28 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $15.05 | 2024 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $14.80 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.09 | 2024 | Cobenfy |
| Indivior INC. | $12.88 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $12.80 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffini Lasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.